Paul Mattels

Stock Analyst at Stifel

(n/a)
# 4,350
Out of 4,711 analysts
4
Total ratings
n/a
Success rate
-20.75%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Paul Mattels

Denali Therapeutics
Dec 16, 2024
Upgrades: Buy
Price Target: $37
Current: $21.45
Upside: +72.49%
Alector
Feb 19, 2020
Initiates: Buy
Price Target: $44
Current: $1.86
Upside: +2,265.59%